SKYE Skye Bioscience, Inc. Year-over-year earnings per share growth for the last twelve months

Skye Bioscience - graphic logo of issuer SKYE

Analyzing the chart on GURU.Markets, we find that the current quarterly EPS rate demonstrates a trend where the value 100.40 serves as the baseline indicator. The operating model of Skye Bioscience, Inc. (SKYE) relies on contract outsourcing for production and marketing. This supports the development of SBI-100 with high pricing power for the treatment of glaucoma, while patent protection for obesity drugs creates barriers for competitors.

skyebioscience.com (SKYE) Quarterly EPS earnings growth: for the period 04/12/2024 - 11/16/2026

Analytical breakdowns for Skye Bioscience, Inc.

- market value and analyst target forecast:
Summary company analytics:Skye Bioscience, Inc. - SKYE
Flagship merchandise of skyebioscience.com

The commercialization dynamics of glaucoma and obesity drugs directly determine the financial stability of Skye Bioscience, Inc. (SKYE). This indicator measures the percentage change in net earnings per share compared to the same period last year. By analyzing quarterly EPS growth, an investor identifies the gap between accounting reports and actual cash flow. A positive trend confirms the effectiveness of cannabinoid drug development, yet signals a risk of overvaluation. Conversely, a decline indicates a fundamental drawdown of capital.

Direct competitors

Indivior Corp (INDV) - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share growth for the last 12 months Collegium Pharmaceutical Inc|CRON (thecronosgroup.com) - Quarterly EPS earnings growth|Quarterly EPS earnings growth canopygrowth.com|Quarterly EPS earnings growth HITI|ACB (Aurora Cannabis, Inc.) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth ACHV (Achieve Life Sciences, Inc)|Anebulo (ANEB) - Earnings per share growth in annualized terms for the last twelve months|Canndoc - Quarterly EPS earnings growth|Year-over-year earnings per one share growth for the last 12 months NTRB (nutriband.com)|Nasus Pharma Ltd (NSRX) - Year-over-year earnings per share growth for the last twelve months|India Globalization Capital - Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months MIRA Pharma|FLGC: Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months IMC (IMCC)|ADIL: Year-over-year net earnings per share trend for the last twelve months|Quarterly EPS earnings growth ARTL (Artelo)|Year-over-year earnings per one share growth for the last 12 months ENSC|Titan Pharmaceuticals - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Greenlane Holdings|inmedpharma.com (INM) - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per share growth for the last 12 months AKAN|Year-over-year earnings per share growth for the last twelve months Enveric Corp|Earnings per share growth in annualized terms for the last twelve months brightgreen.us BGXX|Year-over-year net earnings per share growth for the last 12 months HPCO (Hempacco Co Inc.)